Evidence map›Paper›PMID 36077734›Full record

ArticleCancers2022

Comparison of Genomic Profiling Data with Clinical Parameters: Implications for Breast Cancer Prognosis.

José A López-Ruiz, Jon A Mieza, Ignacio Zabalza, María D M Vivanco

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

José A López-RuizBreast Imaging, PRETEIMAGEN Radiological Group, Manuel Allende 13, 48010 Bilbao, Spain.
Jon A MiezaDepartment of Oncological Gynecology, Cruces University Hospital, 48903 Barakaldo, Spain.
Ignacio ZabalzaPathology Department, Galdakao University Hospital, 48960 Galdakao, Spain.
María D M VivancoCancer Heterogeneity Lab, CIC bioGUNE, Basque Research and Technology Alliance, BRTA, Technological Park of Bizkaia, 48160 Derio, Spain.

Funding

Elkartek KK-2020/00008Spanish Ministry of Science and Innovation PID2020-118464RB-I00
6 · The paper itself

Abstract

Precise prognosis is crucial for selection of adjuvant therapy in breast cancer. Molecular subtyping is increasingly used to complement immunohistochemical and pathological classification and to predict recurrence. This study compares both outcomes in a clinical setting. Molecular subtyping (MammaPrint

Indexed as

breast cancergenomic profileIHCMammaPrintpathological and molecular subtypingprognosisSymphonyTN

Identifiers

PMID36077734
PMCPMC9454811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.